Fig. 2From: Patient-reported outcomes of baricitinib in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatmentChange from baseline over time in the Physical Component Score (PCS) (a) and Mental Component Score (MCS) (b) of the Short Form-36 (SF-36). The dashed line represents the minimum clinically important difference (MCID) in the SF-36 PCS (≥ 5 points) and SF-36 MCS (≥ 5 points). MTX methotrexateBack to article page